載入中
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
收盤時
US$4.03
−US$0.05 · -1.23%
盤後
US$4.03
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
日內區間
目前US$4.03
52週區間
目前US$4.03
盤中時間採用ET。市場資料可能有所延遲。
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
日內區間
目前US$4.03
52週區間
目前US$4.03
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2060.1萬 USD | 374.6萬 USD | 1.4億 USD | 509.1萬 USD | 1316.3萬 USD |
| 銷貨成本 | — | — | 1562.4萬 USD | 62.8萬 USD | 31.2萬 USD |
| 毛利 | 2060.1萬 USD | 374.6萬 USD | 1.25億 USD | 446.3萬 USD | 1285.1萬 USD |
| 研究與開發 | 2228萬 USD | 2640.5萬 USD | 3092.8萬 USD | 2725.9萬 USD | 2377.3萬 USD |
| 銷售、一般及管理費用 | 1439.5萬 USD | 1445.8萬 USD | 2092萬 USD | 6296.1萬 USD | 4991.6萬 USD |
| 營業費用 | 3667.5萬 USD | 4086.3萬 USD | 5184.8萬 USD | 9022萬 USD | 7368.9萬 USD |
| 利息收入 | 217.7萬 USD | 429.1萬 USD | 395.4萬 USD | 141.5萬 USD | 2.4萬 USD |
| 利息支出 | 17.3萬 USD | 255.4萬 USD | 612.4萬 USD | 678.7萬 USD | 396.3萬 USD |
| 折舊和攤銷 | 31.2萬 USD | 172.6萬 USD | 58萬 USD | 60.6萬 USD | 37.9萬 USD |
| 營業利益 | −1607.4萬 USD | −3711.7萬 USD | 7266.9萬 USD | −8575.7萬 USD | −6083.8萬 USD |
| 淨利 | −860.9萬 USD | −2128.8萬 USD | 6704.1萬 USD | −6280.9萬 USD | −3286.6萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年6月1日 | 1:8 | — | — |
股票分割 | 2020年7月17日 | 1:10 | — | — |
已生效 2026年6月1日
1:8
已生效 2020年7月17日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI152.34萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF67.05萬0.00%954億 USD0.05%US$233.52-0.63%
EA Bridgeway Omni Small-Cap Value ETFBSVO6萬—23.91億 USD0.45%US$28.50+0.46%
Dimensional - US Small Cap ETFDFAS2.12萬0.00%338.69億 USD0.31%US$78.17-0.23%
U.S. Micro Cap Portfolio ETFDFMC1.97萬0.00%75.58億 USD0.43%US$57.70-0.20%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9294.240.00%61.81億 USD0.26%US$68.32+0.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFEA Bridgeway Omni Small-Cap Value ETFBSVODimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
